Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,456 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,550 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02252978 | Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00272038 | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | completed | Phase 2 | 29 | Oncology Specialists, S.C.OTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02215161 | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 2 | 14 | University of California, San FranciscoOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00090545 | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2018 | clinicaltrials |
| NCT00188513 | Intensity Modulated Radiation Therapy - Prostate Cancer | completed | Phase 1 / Phase 2 | 267 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01220973 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01521949 | Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA | completed | Phase 2 | 21 | University of Colorado, DenverOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01796028 | Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer(TAXOMET) | completed | Phase 2 | 100 | Centre Antoine LacassagneOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01845792 | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | terminated | Phase 2 | 7 | University of Colorado, DenverOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01620593 | Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer | completed | Phase 2 | 41 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 23, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT03516045 | A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer | unknown | Phase 1 / Phase 2 | 65 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03525652 | Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT00006101 | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | completed | Phase 2 | 76 | Thomas E. AhleringOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | completed | Phase 2 | 136 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 9, 2018 | clinicaltrials |
| NCT01821404 | Atorvastatin Before Prostatectomy and Prostate Cancer(ESTO1) | completed | Phase 2 | 160 | Tampere University HospitalOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT02130700 | Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer | completed | Phase 2 | 17 | Innocrin PharmaceuticalINDUSTRY | 1 | May 7, 2018 | clinicaltrials |
| NCT01857817 | Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer | terminated | Phase 2 | 35 | Vicus TherapeuticsINDUSTRY | 1 | Apr 26, 2018 | clinicaltrials |
| NCT01929655 | Japanese BAY88-8223 Monotherapy Phase II Study | completed | Phase 2 | 49 | BayerINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00089609 | Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00513071 | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01890096 | A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 174 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02313298 | Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer | unknown | Phase 2 | 80 | National Cancer Centre, SingaporeOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 137 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00888654 | Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 41 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01393730 | Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 40 | Mary-Ellen Taplin, MDOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00860158 | Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | terminated | Phase 2 | 1 | Noah Hahn, M.D.OTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01188408 | Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01496131 | Tecemotide (L-BLP25) in Prostate Cancer | completed | Phase 2 | 28 | EMD SeronoINDUSTRY | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02796807 | Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer | completed | Phase 2 | 88 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 6, 2018 | clinicaltrials |
| NCT02958787 | Vessel Sparing Prostate Radiation Therapy | completed | Phase 2 | 135 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02606123 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | ESSA PharmaceuticalsINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01289067 | Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | completed | Phase 2 | 13 | William K. OhOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | terminated | Phase 2 | 22 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003516 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | terminated | Phase 2 | 16 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02097303 | Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis(eRADicAte) | completed | Phase 2 | 36 | Carolina Research Professionals, LLCOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00003534 | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00983710 | Prostate Cancer Symptom Management for Low Literacy Men | completed | Phase 2 | 108 | Baylor College of MedicineOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01105338 | Lycopene or Green Tea for Men at Risk of Prostate Cancer(ProDiet) | completed | Phase 2 / Phase 3 | 126 | University of BristolOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT00814788 | Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer(UCDCC#215) | completed | Phase 2 | 24 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01199146 | Abiraterone Post Ketoconazole for Prostate Cancer | completed | Phase 2 | 42 | University of California, San FranciscoOTHER | 1 | Jan 8, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jul 5, 2018source: clinicaltrials